Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

OBJECTIVE: Metabolic syndrome (MetS) is a cluster of concurrent risk factors for cardiovascular disease and type 2 diabetes. This post hoc analysis explored key efficacy and safety endpoints in patients with psoriatic arthritis (PsA) and MetS treated with tofacitinib. METHODS: Tofacitinib 5 and 10 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T., Giles, Jon T., Ogdie, Alexis, Gomez‐Reino, Juan J., Helliwell, Philip, Young, Pamela, Wang, Cunshan, Wu, Joseph, Romero, Ana Belén, Woolcott, John, Stockert, Lori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571390/
https://www.ncbi.nlm.nih.gov/pubmed/32910531
http://dx.doi.org/10.1002/acr2.11166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571390/
https://www.ncbi.nlm.nih.gov/pubmed/32910531
http://dx.doi.org/10.1002/acr2.11166

Ejemplares similares